Heska Corporation (NASDAQ:HSKA) had its price objective cut by investment analysts at B. Riley from $96.50 to $93.00 in a note issued to investors on Friday. The firm currently has a “neutral” rating on the medical research company’s stock. B. Riley’s target price points to a potential upside of 13.75% from the company’s previous close.
HSKA has been the topic of a number of other reports. Canaccord Genuity started coverage on shares of Heska Corporation in a research note on Thursday, October 5th. They issued a “buy” rating and a $115.00 price objective on the stock. Zacks Investment Research cut shares of Heska Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Benchmark Co. increased their price objective on shares of Heska Corporation from $106.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. BidaskClub cut shares of Heska Corporation from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Finally, Aegis increased their price objective on shares of Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a research note on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $106.25.
Heska Corporation (NASDAQ:HSKA) last issued its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.01. The firm had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The firm’s revenue was down 6.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.45 EPS.
In other Heska Corporation news, EVP Nancy Wisnewski sold 825 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $102.21, for a total transaction of $84,323.25. Following the sale, the executive vice president now directly owns 38,114 shares of the company’s stock, valued at approximately $3,895,631.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO John Mcmahon sold 2,608 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total transaction of $263,851.36. Following the sale, the chief financial officer now directly owns 193 shares in the company, valued at $19,525.81. The disclosure for this sale can be found here. 14.70% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. acquired a new stake in shares of Heska Corporation in the first quarter worth approximately $101,000. Royal Bank of Canada boosted its position in shares of Heska Corporation by 96.9% in the second quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after acquiring an additional 499 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Heska Corporation in the second quarter worth approximately $127,000. LS Investment Advisors LLC boosted its position in shares of Heska Corporation by 411.2% in the second quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after acquiring an additional 1,028 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan acquired a new stake in shares of Heska Corporation in the second quarter worth approximately $154,000. 80.46% of the stock is currently owned by institutional investors.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
What are top analysts saying about Heska Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heska Corporation and related companies.